DG
Therapeutic Areas
NysnoBio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Gene Therapy for PARKIN-PD | Parkinson's Disease (Parkin mutation-associated) | Preclinical |
Leadership Team at NysnoBio
JA
Jennifer A. Johnston, PhD
Cofounder and CEO
DM
David M. Weiner, MD
Chief Medical Officer
EH
Elizabeth Higgins, PhD
Chief Technology Officer
CG
Christina Gamba-Vitalo, PhD
Head of in vivo Pharmacology and Toxicology
RM
Ron Mandel, PhD
Head of Gene Therapy Programs